Popular Articles

Measurements Fail To Identify TB Patients Who Could Benefit From Shorter Treatment Course
Tuberculosis (TB) is a difficult infection to treat and requires six months of multiple antibiotics to cure it. To combat the TB pandemic, a shorter and simpler drug treatment would be a huge advance since most TB occurs in re-limited settings with poor public health infrastructures.
generic viagra online
Data Presented At Society Of Nuclear Medicine 2009 Annual Meeting Supports Potential Of Peregrine's Cotara(R) For The Treatment Of Brain Cancer
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that researchers will present data at the SNM 2009 Annual Meeting showing that its brain cancer agent Cotara(R) specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs. Cotara is a targeted monoclonal antibody linked to a radioisotope being developed as a potential new treatment for glioblastoma multiforme (GBM), a deadly form of brain cancer. The results reported from an ongoing dosimetry study at U.S. brain cancer centers show that in patients dosed in the first two cohorts of the study, the concentration of Cotara in brain tumors was on average more than 300-fold higher than in other normal organs. In addition, these patients have all either met or exceeded the expected median survival time of six months for recurrent GBM patients. Cotara is currently being tested in this Phase I dose response and dosimetry trial and in a Phase II clinical trial in recurrent GBM patients.
News of the day
Phase II Study Of Sunitinib In Men With Advanced Prostate Cancer
UroToday.com - In the Annals of Oncology, Dr. Dror Michaelson and associates reported Phase II data on the efficacy and safety of the tyrosine kinase inhibitor sunitinib in patients with castration-resistant prostate cancer (CRPC). Sunitinib inhibits vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), both elevated in prostate cancer (CaP).
Cardiovascular

MS Societies In UK And Australia Provide International Research Opportunity

Worldwide collaborative ties among researchers investigating the debilitating neurological condition multiple sclerosis (MS) have been strengthened thanks to the introduction of the first UK and Australian Fellowship Exchange programme. Dr Julia Morahan is the first person to be awarded the Macquarie Group Foundation Australia and UK MS Society Fellowship and she makes the move from investigating Motor Neurone Disease to research into MS. The initiative cements the relationship between the UK MS Society and international scientists researching MS and is supported by the Macquarie Group Foundation - the philanthropic arm of Macquarie Group. Dr Lee Dunster, Head of Research and Information at the UK MS Society, said: "More than 2.5million people are living with MS around the world and there is some suggestion this number is rising. "It is clear that no one scientist or laboratory will alone discover MS prevention or cure and by offering such research opportunities, the UK MS Society and MS Research Australia are helping to link world-class knowledge for the benefit of people living with MS." Dr Morahan will work in the internationally recognised laboratory of Professor George Ebers at the University of Oxford. The 3-year award will fund research aiming to map gene regions linked with MS and determine how they influence whether or not people get MS. Dr Morahan said: "It was originally thought that one particular gene was implicated in MS but potentially three or four genes are involved. I"ll be looking at isolating those genes. "The area of the genome where these genes are found is so complex. It controls what makes people"s cells unique," she added. The new initiative backs a new five-year strategy for the MS Society, which aims to further build on collaborative research that already exists with organisations in both Australia and America. Jeremy Wright, Executive Director of MS Research Australia, said: "As a young scientist in the area of neuroscience, Dr Morahan has already added to the understanding of MND. I am delighted that she is using her scientific prowess to help people with MS. "The Fellowship furthers MS Research Australia"s aim of creating international links to take advantage of research strengths in other countries. It also provides the opportunity to train Australian scientists in cutting-edge technology. We are indebted to the Macquarie Group Foundation which has been instrumental in getting this Fellowship established." Julie White, Head of the Macquarie Group Foundations, said: "The Macquarie Group Foundation has supported health research in Australia for more than 36 years. "A growing incidence of MS prompted the establishment of the Macquarie Group Foundation International MS Fellowship to strengthen research collaborations between Australia and the UK to help find a cure. We wish Dr Morahan every success in her pioneering scientific work in a disease category where there is so much hope." MS Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):